Intralipid IV for Fertility: What to Know Before Your Embryo Transfer

For patients going through IVF, every step of the fertility journey can feel important, especially when preparing for an embryo transfer. If you have experienced recurrent implantation failure, recurrent pregnancy loss, recurrent miscarriages, or failed IVF cycles, your fertility specialist may discuss additional therapies that could potentially support your treatment plan.

One therapy that has received increasing attention is Intralipid IV for fertility.

Originally developed for parenteral nutrition, Intralipid is an intravenous fat emulsion containing soybean oil, egg phospholipids, glycerin, and water. Researchers have studied whether an Intralipid infusion may have immunomodulatory effects that could be relevant for certain patients undergoing IVF.

At ASAP IVs, we offer Intralipid 20% intravenous infusion therapy and work in conjunction with your Reproductive Endocrinologist to coordinate treatment around your fertility plan.

What Is Intralipid Therapy?

Intralipid is an intravenous fat emulsion that has traditionally been used as a source of calories and essential fatty acids in parenteral nutrition. Its ingredients include soybean oil, egg phospholipids, and glycerin.

In fertility care, Intralipid therapy has been investigated as a form of adjunctive immunotherapy because of its potential effects on the immune system, particularly natural killer (NK) cells and NK cell activity.

Researchers have explored whether immune system activity may play a role in certain cases of recurrent implantation failure and recurrent pregnancy loss. This has led to interest in therapies that may influence the immune response surrounding embryo implantation.

However, Intralipid is not considered a routine fertility treatment for everyone undergoing IVF. Research is ongoing, and patients should discuss the potential risks, benefits, and limitations with their Reproductive Endocrinologist.

Why Is Intralipid Used During IVF?

Successful IVF involves many different factors, from egg and embryo quality to hormonal support, endometrial receptivity, and the timing of embryo transfer.

Researchers have also investigated the relationship between immune function and embryo implantation. In particular, natural killer cells have received attention because of their role within the immune system and their potential relationship with implantation and pregnancy.

This has led researchers to investigate Intralipid infusion as a possible adjunct treatment for certain patients, including those with:

• Recurrent implantation failure

• Recurrent pregnancy loss

• Recurrent miscarriages

• Multiple failed IVF cycles

• Unexplained infertility

• Certain immune-related concerns identified by their fertility specialist

Importantly, these conditions can have many different causes. Intralipid therapy is not appropriate for every patient experiencing infertility or pregnancy loss, and it should not replace a comprehensive evaluation or established fertility treatments.

What Does the Research Say About Intralipid Infusion and IVF?

Research into Intralipid and IVF has produced encouraging findings, but the evidence is not yet definitive.

A 2021 systematic review and meta-analysis evaluated five randomized controlled trials involving 840 patients. Researchers reported higher clinical pregnancy rates, ongoing pregnancy rates, and live birth rates among patients receiving Intralipid compared with control groups. The study did not find a statistically significant reduction in miscarriage rate.

Another systematic review focusing on women with previous implantation failure found potentially higher clinical pregnancy and live birth rates with Intralipid. However, researchers rated the quality of evidence as low, and when higher-risk studies were removed from the analysis, the differences were no longer statistically significant.

For this reason, Intralipid should be viewed as an adjunctive therapy being studied in reproductive medicine rather than a guaranteed method of improving IVF success.

Patients interested in a deeper look at the published research can read our article on Intralipid therapy for IVF.

Intralipid, Natural Killer Cells, and the Immune System

One reason Intralipid has generated interest in fertility medicine is its possible effect on natural killer (NK) cells.

NK cells are a normal part of the immune system. Researchers have investigated whether altered NK cell activity may be associated with reproductive outcomes in certain patient populations, particularly those experiencing recurrent implantation failure or recurrent pregnancy loss.

Intralipid has been studied for its potential immunomodulatory effects, including its possible ability to influence NK cell activity. However, reproductive immunology is complex, and the relationship between NK cells, infertility, miscarriage, and IVF outcomes remains an area of active research.

Testing for NK cells or using immune-based therapies should therefore be discussed with your Reproductive Endocrinologist rather than considered a standard part of every IVF cycle.

How Does Intralipid Compare With Other IVF Adjuncts?

Patients undergoing fertility treatments may encounter a variety of therapies intended to support implantation or pregnancy. Depending on an individual's medical history, discussions may include IVIG, corticosteroids, steroids, aspirin, progesterone, platelet-rich plasma (PRP), or other forms of immunotherapy.

These therapies work in different ways and are not interchangeable.

For example, progesterone is commonly used as hormonal support during certain fertility treatment protocols, while aspirin or corticosteroids may be recommended for specific medical indications. IVIG is a different intravenous immunotherapy that has also been studied in patients with recurrent pregnancy loss or failed IVF cycles.

Conditions such as antiphospholipid syndrome may also require their own specific evaluation and treatment plan.

Your fertility specialist can determine which, if any, adjunctive treatments are appropriate based on your medical history, previous IVF cycles, laboratory findings, and overall fertility plan.

ASAP IVs' Intralipid IV Protocol for Fertility

Based on published research and our review of different dosing protocols, ASAP IVs offers a higher-dose Intralipid protocol. We are happy to coordinate with your Reproductive Endocrinologist so that your infusion fits appropriately into your IVF and embryo transfer schedule.

Our protocol includes:

1. Intralipid preparation

100mL of 20% Intralipid Emulsion Therapy is diluted into 250mL or 500mL of IV fluid using Normal Saline or Lactated Ringer's solution.

2. Intravenous infusion

IV access is established and the Intralipid infusion begins. Treatment typically takes approximately 60 to 120 minutes, depending on patient comfort.

During your intravenous infusion, you will be monitored for safety and comfort. Side effects are uncommon and are typically mild, but your medical team will review relevant risks and precautions with you.

3. Timing around embryo transfer

Timing can be coordinated with your Reproductive Endocrinologist based on your individual IVF protocol. Intralipid IV can also be scheduled approximately 1 to 7 days before embryo transfer when appropriate.

Who May Consider Intralipid IV for Fertility?

Intralipid therapy may be discussed by a fertility specialist for certain patients with a history of unsuccessful fertility treatments, recurrent implantation failure, recurrent pregnancy loss, or unexplained infertility.

That does not mean every patient with these conditions will benefit from Intralipid.

Fertility and embryo implantation are influenced by many variables, including embryo quality, age, uterine and endometrial factors, genetics, underlying medical conditions, hormonal factors, and treatment protocol.

An Intralipid infusion should therefore be considered within the context of your complete fertility treatment plan rather than as a standalone solution.

When Is Intralipid Given During IVF?

There is no single universally established Intralipid schedule for IVF.

Published studies have used different dosages and treatment schedules, including administration before embryo transfer, around the time of transfer, and additional infusions following a positive pregnancy test.

At ASAP IVs, treatment timing can be coordinated directly with your Reproductive Endocrinologist. When appropriate, our Intralipid infusion can be scheduled 1 to 7 days before your embryo transfer.

Your fertility specialist's recommendations should always take priority when determining when and whether treatment is appropriate.

Is Intralipid IV Safe?

Intralipid has a long history of medical use as a component of parenteral nutrition. However, as with any intravenous therapy, there are potential risks and contraindications.

Because Intralipid contains soybean oil and egg phospholipids, patients should tell their medical team about allergies to soy, eggs, or any other ingredients before receiving treatment.

Your provider should also review your medical history, medications, allergies, and fertility treatment plan before your infusion.

Does Intralipid Improve IVF Success Rates?

Some studies and meta-analyses have reported improvements in implantation and clinical pregnancy rates among selected IVF patients receiving Intralipid therapy. Other research has found less convincing results, and differences in study design, patient populations, dosage, and treatment protocols make it difficult to draw definitive conclusions.

Current evidence therefore does not establish Intralipid as a standard treatment for every patient undergoing IVF.

Instead, it may be considered an adjunctive therapy for selected patients after discussion with their fertility specialist.

Intralipid IV Therapy With ASAP IVs

Fertility treatment can involve countless appointments, medications, tests, and procedures. Our goal at ASAP IVs is to make the Intralipid infusion portion of your treatment as convenient and comfortable as possible.

We can work alongside your Reproductive Endocrinologist to coordinate your infusion according to your prescribed fertility treatment schedule.

If your fertility specialist has recommended Intralipid therapy, or you would like to discuss whether an Intralipid IV before embryo transfer may fit into your care plan, contact ASAP IVs to learn more or schedule an appointment.

Intralipid therapy is an adjunctive treatment and is not proven to improve fertility or IVF outcomes for every patient. Treatment should be undertaken in consultation with a qualified fertility specialist.